{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:34:11Z","timestamp":1782862451396,"version":"3.54.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/olq.0b013e318285c6d2","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T07:04:54Z","timestamp":1360652694000},"page":"197-201","source":"Crossref","is-referenced-by-count":373,"title":["The Estimated Direct Medical Cost of Selected Sexually Transmitted Infections in the United States, 2008"],"prefix":"10.1097","volume":"40","author":[{"given":"Kwame","family":"Owusu-Edusei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrell W.","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Gift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Cheryl Ba\u00f1ez","family":"Ocfemia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte K.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1363\/3601104","article-title":". The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.","volume":"36","author":"Chesson","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/OLQ.0b013e318223be77","article-title":". A brief review of the estimated economic burden of sexually transmitted diseases in the United States: Inflation-adjusted updates of previously published cost studies.","volume":"38","author":"Chesson","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1363\/3600604","article-title":"Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000.","volume":"36","author":"Weinstock","year":"2004","journal-title":"Perspect Sex Reprod Health"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"e17502","DOI":"10.1371\/journal.pone.0017502","article-title":". Estimated HIV incidence in the United States, 2006-2009.","volume":"6","author":"Prejean","year":"2011","journal-title":"PLoS One"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/OLQ.0b013e318286bb53","article-title":". Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008.","volume":"40","author":"Satterwhite","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/OLQ.0b013e3181d73e4c","article-title":". The direct cost of chlamydial infections: Estimates for the employer-sponsored privately insured population in the United States, 2003-2007.","volume":"37","author":"Owusu-Edusei","year":"2010","journal-title":"Sex Transm Dis"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007435-198904000-00004","article-title":"The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic.","volume":"16","author":"Begley","year":"1989","journal-title":"Sex Transm Dis"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/01.olq.0000235149.41948.fa","article-title":"The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims.","volume":"33","author":"Gift","year":"2006","journal-title":"Sex Transm Dis"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00007435-200305000-00001","article-title":"3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease.","volume":"30","author":"Yeh","year":"2003","journal-title":"Sex Transm Dis"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00007435-199909000-00001","article-title":". Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections.","volume":"26","author":"Foglia","year":"1999","journal-title":"Sex Transm Dis"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1086\/652395","article-title":". Risk of sequelae after Chlamydia trachomatis genital infection in women.","volume":"201","author":"Haggerty","year":"2010","journal-title":"J Infect Dis"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"389","DOI":"10.7326\/0003-4819-124-4-199602150-00002","article-title":"Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis.","volume":"124","author":"Magid","year":"1996","journal-title":"Ann Intern Med"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/OLQ.0b013e3181c5e643","article-title":"Treatment cost of acute gonococcal infections: estimates from employer-sponsored private insurance claims data in the United States, 2003-2007.","volume":"37","author":"Owusu-Edusei","year":"2010","journal-title":"Sex Transm Dis"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.olq.0000175414.80023.59","article-title":". A cost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhea or chlamydia at public sexually transmitted disease clinics.","volume":"32","author":"Gift","year":"2005","journal-title":"Sexually Transm Dis"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amepre.2008.03.028","article-title":". Economic evaluation of delivering hepatitis B vaccine to injection drug users.","volume":"35","author":"Hu","year":"2008","journal-title":"Am J Prev Med"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/07448480309596355","article-title":"The cost effectiveness of hepatitis immunization for US college students.","volume":"51","author":"Jacobs","year":"2003","journal-title":"J Am Coll Health"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0264-410X(02)00457-7","article-title":"Cost-effectiveness of hepatitis B vaccination of prison inmates.","volume":"21","author":"Pisu","year":"2002","journal-title":"Vaccine"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.1995.03530150025029","article-title":". Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.","volume":"274","author":"Margolis","year":"1995","journal-title":"JAMA"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":". The lifetime cost of current human immunodeficiency virus care in the United States.","volume":"44","author":"Schackman","year":"2006","journal-title":"Med Care"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.qai.0000243090.32866.4e","article-title":". The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.","volume":"43","author":"Hutchinson","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/cid\/ciq243","article-title":". The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.","volume":"52","author":"Gardner","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1001\/jama.2009.828","article-title":"Universal voluntary testing and treatment for prevention of HIV transmission.","volume":"301","author":"Dieffenbach","year":"2009","journal-title":"JAMA"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00042560-199709010-00009","article-title":"Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs.","volume":"16","author":"Holtgrave","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":". Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"},{"key":"R29-3-20210213","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.vaccine.2008.06.045","article-title":". The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination.","volume":"26","author":"Chesson","year":"2008","journal-title":"Vaccine"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007435-200210000-00008","article-title":"3rd, et al.. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States.","volume":"29","author":"Fisman","year":"2002","journal-title":"Sex Transm Dis"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/OLQ.0b013e3181f4207f","article-title":"Estimating the direct outpatient medical cost per episode of primary and secondary syphilis in the United States: Insured population perspective, 2003-2007.","volume":"38","author":"Owusu-Edusei","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/OLQ.0b013e318199d5fe","article-title":". Estimates of the direct cost per case and overall burden of trichomoniasis for the employer- sponsored privately insured women population in the United States, 2001 to 2005.","volume":"36","author":"Owusu-Edusei","year":"2009","journal-title":"Sex Transm Dis"}],"container-title":["Sexually Transmitted Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/OLQ.0b013e318285c6d2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:57:59Z","timestamp":1620953879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007435-201303000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/olq.0b013e318285c6d2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.720847221.793501526","asserted-by":"object"}]},"ISSN":["0148-5717"],"issn-type":[{"value":"0148-5717","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}